Oxford Biomedica is a global vector-agnostic gene and cell therapy CDMO.



  • Long-term advisor since 2003
  • World leading gene and cell therapy group and FTSE250 constituent of LSE’s Main Market



  • Day to day strategic advice, sounding board and positioning of investment case including multiple deals, significant newsflow, evolution of the company’s strategy, financial results and financing rounds.
  • Recent major events include a $227 million agreement with Juno Therapeutics (Bristol-Myers Squibb), Oxford Biomedica’s pivotal role in the manufacture of the AstraZeneca / Oxford COVID-19 vaccine and the formation of a new US-based subsidiary, Oxford Biomedica Solutions, a high-performing, full scope Adeno-Associated Virus (AAV) Manufacturing and Innovation Business.



  • Positioned investment case across transactions in line with strategy
  • Continued high quality and strategically placed coverage across international, trade and business media
  • Strong international analysts support, including the US
  • Upgraded shareholder base and increased awareness with international investors